Clinical Trials Logo
  1. Home
  2. Liver Metastases
  3. NCT01233544
  4. Details
NCT01233544 Clinical Trial

Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases

Liver Metastases Clinical Trial

— RAS01  

Official title:
The International Liver Tumor Group RAS-trial Radiofrequency Ablation Versus Stereotactic Body Radiation Therapy for Colorectal Liver Metastases: A Randomized Trial

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT01233544
Other study ID # RAS 01
Secondary ID
Status Terminated
Phase Phase 3
First received November 2, 2010
Last updated May 11, 2016
Start date September 2010
Est. completion date December 2014

Study information
Verified date May 2015
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority Sweden: Regional Ethical Review Board
Study type Interventional

Clinical Trial Summary

This randomized clinical phase III trial is testing the efficacy of radiofrequency ablation (RFA) and stereotactic body radiotherapy (SBRT) in the treatment of colorectal carcinoma liver metastases.

Primary end point is local progression free survival.

Description:

Patients with 1-4 inoperable colorectal liver metastases, no more 4 cm in diameter are randomized to either RFA or SBRT. Primary end point i local progression free survival. Chemotherapy is allowed before and after study treatment.

Recruitment information / eligibility
Status Terminated
Enrollment 300
Est. completion date December 2014
Est. primary completion date December 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria:

- Adenocarcinoma of the colon or rectum

- Liver metastases

- Inoperable (technical or medical)

- 1-4 metastases

- Maximum 40 mm in diameter

- Suitable for both therapies, RFA and SBRT

Exclusion Criteria:

- Uncontrolled extrahepatic disease and uncontrolled primary cancer

- Liver cirrhosis

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Procedure:
• SBRT or RFA
Patients are allocated to one of the two arms in a 1:1 randomization

Locations
Country Name City State
Denmark Aarhus University Hospital Aarhus C
Sweden Karolinska Institute, Huddinge Stockholm

Sponsors (2)
Lead Sponsor Collaborator
University of Aarhus Danish Center for Interventional Research in Radiation Oncology (CIRRO)

Countries where clinical trial is conducted

Denmark,  Sweden, 

Outcome
Type Measure Description Time frame Safety issue
Primary Local progression-free survival 3 years No
Secondary Toxicity 3 years Yes
Secondary Survival 3 years No
Secondary Progression (local or distant) 3 years No
Secondary Quality of life 3 years No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT04837885 - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases Phase 2
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Not yet recruiting NCT04520737 - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases N/A
Terminated NCT02465112 - Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor Phase 3
Completed NCT02352259 - Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II Phase 2
Active, not recruiting NCT01763450 - Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer Phase 2
Withdrawn NCT01631539 - Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC N/A
Recruiting NCT01250158 - Liver-PILP First-in-Man N/A
Completed NCT01347333 - Stereotactic Body Radiotherapy for Liver Tumors N/A
Completed NCT00587756 - Alternative to Two-Stage Hepatectomy N/A
Completed NCT01683357 - Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases N/A
Completed NCT04942665 - Low Dose ICG for Biliary Tract and Tumor Imaging Phase 2
Not yet recruiting NCT05354674 - Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
Recruiting NCT04616495 - Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
Not yet recruiting NCT04509635 - Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis Phase 3
Recruiting NCT04178759 - Impact of Chemotherapy and Regenerative Markers of Liver Regeneration After Liver Resection for Liver Metastases N/A
Completed NCT05036265 - Prognostic Factors and Oncological Outcomes in Laparoscopic Liver Resection for CRLM

External Links